LVW Advisors LLC Has $306,000 Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

LVW Advisors LLC lifted its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 50.2% during the 1st quarter, Holdings Channel reports. The firm owned 1,957 shares of the company’s stock after purchasing an additional 654 shares during the quarter. LVW Advisors LLC’s holdings in BeiGene were worth $306,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BGNE. Toronto Dominion Bank boosted its holdings in BeiGene by 166.4% in the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after acquiring an additional 208 shares in the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of BeiGene during the fourth quarter valued at approximately $98,000. PNC Financial Services Group Inc. increased its position in shares of BeiGene by 123.9% during the third quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock valued at $132,000 after acquiring an additional 405 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of BeiGene during the fourth quarter valued at approximately $183,000. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of BeiGene during the fourth quarter valued at approximately $208,000. Institutional investors own 48.55% of the company’s stock.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 26,716 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Julia Aijun Wang sold 899 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $155.66, for a total value of $139,938.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the sale, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,927 shares of company stock valued at $4,965,913. Corporate insiders own 7.43% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on BGNE. Bank of America decreased their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research report on Monday, April 8th. TD Cowen increased their price target on BeiGene from $236.00 to $254.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Sanford C. Bernstein decreased their target price on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. raised their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $251.93.

BeiGene Trading Down 2.0 %

BGNE opened at $142.67 on Monday. The business’s 50-day moving average price is $156.93 and its 200-day moving average price is $159.56. The company has a current ratio of 2.08, a quick ratio of 1.84 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $225.23.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) EPS for the quarter, beating analysts’ consensus estimates of ($3.07) by $0.66. The business had revenue of $751.70 million during the quarter, compared to analyst estimates of $670.09 million. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. BeiGene’s quarterly revenue was up 67.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($3.34) EPS. On average, analysts expect that BeiGene, Ltd. will post -8.2 EPS for the current year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.